Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.
Erlinda M Gordon, K Kumar Sankhala, Neal Chawla...
https://pubmed.ncbi.nlm.nih.gov/27234989/Actively Recruiting
Led by Sarcoma Oncology Research Center, LLC · Updated on 2025-02-24
250
Participants Needed
1
Research Sites
30 weeks
Total Duration
Researchers are evaluating the safety and appropriate dosing of a combination of three drugsTrabectedin, Ipilimumab, and Nivolumabin adults with advanced soft tissue sarcoma who have received prior treatment. This phase 12 open-label study builds on earlier trial results to find the highest dose patients can safely tolerate and to assess safety and potential effectiveness in a larger group. During the dose escalation phase, small groups of patients receive increasing doses of Trabectedin intravenously every three weeks, alongside fixed doses of Ipilimumab every 12 weeks and Nivolumab every two weeks. The maximum tolerated dose is identified by monitoring for dose-limiting toxicities. In the expansion phase, more patients receive the identified safe dose of Trabectedin with the same fixed doses of the other two drugs. Some patients may undergo surgery after treatment cycles, and tissue samples will be analyzed to study the drugs effects. Participants attend regular visits for treatment and monitoring up to one year or until disease progression or unacceptable side effects. Assessments include scans, laboratory tests, and tissue analyses to evaluate response and immune activity in tumors. Researchers measure the maximum tolerated dose and monitor response rates, disease control, progression-free survival, and overall survival over 24 months. Safety and treatment effects are closely followed throughout the study.
CONDITIONS
SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma
E
Erlinda M Gordon, MD
V
Victoria Chua-Alcala, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Sarcoma Oncology Research Center, LLC
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational combination (SAINT trial) | Current standard chemotherapy (context) |
|---|---|---|
| What it is | A combination of trabectedin with the immune checkpoint inhibitors ipilimumab and nivolumab given sequentially per the SAINT trial protocol. | Anthracycline‑based systemic chemotherapy (for example, doxorubicin alone or with ifosfamide) is current standard treatment for previously treated advanced soft tissue sarcoma. |
| Role in trial | Investigational regimen evaluated in a single‑group early‑phase study. | Not evaluated in this trial but represents routine care outside the study. |
| Primary use | To determine the tolerability (phase 1) and initial anti‑tumor activity (phase 2) of the combination in previously treated patients. | Used to control disease after initial treatments fail in advanced soft tissue sarcoma. |
| How it is given or performed | Trabectedin is infused every three weeks combined with ipilimumab every 12 weeks and nivolumab every two weeks, per trial protocol. | Doxorubicin is typically administered intravenously every three weeks, with or without ifosfamide depending on regimen. |
| Evidence status | Early data suggest safety and potential activity, but randomized trials are needed to compare with standard therapy. | Anthracycline‑based chemotherapy has established benefit in advanced STS with known response and survival outcomes. |
| Important risks | Potential for hematologic toxicity, liver enzyme elevation, immune-related side effects from ipilimumab and nivolumab. | Known risks include cardiotoxicity, myelosuppression, and organ dysfunction depending on regimen. |
| Important limitations | Findings are preliminary from a non‑randomized phase 1/2 study and need confirmation in randomized trials. | Modest activity and substantial toxicity in some patients limit its use; many patients progress after chemotherapy. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 year
Participants receive escalating doses of Trabectedin every 3 weeks, combined with Ipilimumab every 12 weeks and Nivolumab every 2 weeks, starting 2 weeks after the first Trabectedin dose. Treatment continues until disease progression, unacceptable toxicity, or up to 9 six-week cycles (one year) of therapy.
Visits every 2 to 3 weeks for drug administration depending on the medication schedule
Duration - Variable based on surgery timing
After one or more treatment cycles, participants may undergo surgical debulking, complete surgical removal, or biopsy. If residual disease is present, repeat treatment cycles may be given 4 weeks after surgery, provided healing and low toxicity.
1 to 2 visits depending on surgery and recovery
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Erlinda M Gordon, K Kumar Sankhala, Neal Chawla...
https://pubmed.ncbi.nlm.nih.gov/27234989/George D Demetri, Margaret von Mehren, Robin L Jones...
https://pubmed.ncbi.nlm.nih.gov/26371143/Sarcoma Oncology Research Center, LLC
Lead Sponsor